Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 0.5959 |
| Open | 0.5890 |
| Bid | 0.6100 x 3000 |
| Ask | 0.6293 x 1000 |
| Day's range | 0.5890 - 0.6483 |
| 52-week range | 0.5560 - 3.3600 |
| Volume | |
| Avg. volume | 269,480 |
| Market cap | 48.682M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3880 |
| Earnings date | 01 Mar 2022 - 07 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- Zacks
Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- GlobeNewswire
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 75,000 shares of common stock to Michael Woloschak, S
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2021. “The recently announced top-line results from Soleno’s ongoing open-label extension study evaluating DCCR for the treatment of Prader-Willi syndrome (PWS), and th
